secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001213900-24-024022
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada reports FY 2023 net loss of $98.8M; advancing Phase 3 MDD trials with data expected H2 2024
--------------------------------------------------------------------------------

- Q4 2023 net loss $25.2M ($0.84/share) vs $37.9M ($1.28) in Q4 2022; full-year net loss $98.8M ($3.28/share).
- Cash, equivalents and short-term investments at Dec 31, 2023: $96.3M, down from $148.3M a year earlier.
- R&D expense fell to $54.8M in FY 2023 from $113.3M in FY 2022, reflecting completion of prior Phase 3 trials.
- REL-1017 Phase 3 Reliance II enrollment on track; top-line data expected H2 2024; Relight enrollment targeted by year-end 2024.
- REL-P11 psilocybin Phase 1 in obese patients expected H1 2024; Phase 2a proof-of-concept data seen H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390024024022/0001213900-24-024022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390024024022/ea0202135-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-024022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer